Biotech Values

[DewDiligence]

New survey: Dual-Oral SVR Rate in Treatment-Naïve HCV

Q: In treatment-naive genotype-1a* patients, what is the worst-case
SVR rate you expect in the first credible trial testing two direct-acting
antiviral agents without interferon or ribavirin?

a) >90%
b) 80-90%
c) 65-80%
d) 50-65%
e) <50%

*Genotype-1a is the most difficult-to-treat common HCV genotype in the US population.


To vote, please go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #146.

Note: You may vote in any listed survey in which you have not already voted.